 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || INO-4500 / Inovio, EBS-Lassa / Emergent Biosolutions
Review, Journal: Lassa fever vaccine candidates: A scoping review of vaccine clinical trials. (Pubmed Central) - Jun 5, 2023
Though LF vaccine development is still in early stages, current progress towards a safe and effective vaccine is encouraging.
- ||| INO-4500 / Inovio
Trial completion, Combination therapy: Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana (clinicaltrials.gov) - Oct 3, 2022
P1, N=220, Completed, Sponsor: Inovio Pharmaceuticals
Though LF vaccine development is still in early stages, current progress towards a safe and effective vaccine is encouraging. Active, not recruiting --> Completed
- || INO-4500 / Inovio
Enrollment closed, Combination therapy: Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana (clinicaltrials.gov) - Nov 22, 2021
P1, N=220, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| INO-4500 / Inovio
Enrollment open, Combination therapy: Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana (clinicaltrials.gov) - Feb 25, 2021
P1, N=220, Recruiting, Sponsor: Inovio Pharmaceuticals
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| INO-4500 / Inovio
Trial completion: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers (clinicaltrials.gov) - Nov 16, 2020
P1, N=60, Completed, Sponsor: Inovio Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || INO-4500 / Inovio
Trial completion date, Trial primary completion date, Combination therapy: Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana (clinicaltrials.gov) - Sep 14, 2020
P1, N=220, Not yet recruiting, Sponsor: Inovio Pharmaceuticals
Active, not recruiting --> Completed Trial completion date: Mar 2022 --> Jun 2022 | Trial primary completion date: Mar 2022 --> Jun 2022
- || INO-4500 / Inovio
Trial completion date, Trial primary completion date, Combination therapy: Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana (clinicaltrials.gov) - Jun 11, 2020
P1, N=220, Not yet recruiting, Sponsor: Inovio Pharmaceuticals
Trial completion date: Mar 2022 --> Jun 2022 | Trial primary completion date: Mar 2022 --> Jun 2022 Trial completion date: Dec 2021 --> Mar 2022 | Trial primary completion date: Dec 2021 --> Mar 2022
- || INO-4500 / Inovio
Trial initiation date, Combination therapy: Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana (clinicaltrials.gov) - Apr 24, 2020
P1, N=220, Not yet recruiting, Sponsor: Inovio Pharmaceuticals
Trial completion date: Dec 2021 --> Mar 2022 | Trial primary completion date: Dec 2021 --> Mar 2022 Initiation date: Mar 2020 --> Jun 2020
- || INO-4500 / Inovio
Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy: Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana (clinicaltrials.gov) - Dec 29, 2019
P1, N=225, Not yet recruiting, Sponsor: Inovio Pharmaceuticals
Initiation date: Mar 2020 --> Jun 2020 Trial completion date: Jul 2021 --> Oct 2021 | Initiation date: Dec 2019 --> Mar 2020 | Trial primary completion date: Jul 2021 --> Oct 2021
- || INO-4500 / Inovio
Enrollment closed: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers (clinicaltrials.gov) - Nov 15, 2019
P1, N=60, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Trial completion date: Jul 2021 --> Oct 2021 | Initiation date: Dec 2019 --> Mar 2020 | Trial primary completion date: Jul 2021 --> Oct 2021 Recruiting --> Active, not recruiting
- | INO-4500 / Inovio
New P1 trial, Combination therapy: Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana (clinicaltrials.gov) - Sep 16, 2019
P1, N=225, Not yet recruiting, Sponsor: Inovio Pharmaceuticals
- ||| INO-4500 / Inovio
Enrollment open: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers (clinicaltrials.gov) - May 12, 2019
P1, N=60, Recruiting, Sponsor: Inovio Pharmaceuticals
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| INO-4500 / Inovio
New P1 trial: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers (clinicaltrials.gov) - Jan 16, 2019
P1, N=60, Not yet recruiting, Sponsor: Inovio Pharmaceuticals